Note: the performance values summarized in this table are study-reported outcomes and should not be interpreted as directly comparable across modalities. The included studies differ in sample size, data type, diagnostic task, preprocessing method, model architecture, validation strategy, and outcome metric. Therefore, the table is intended to provide an overview of reported AI applications rather than a ranking of EEG-, MRI-, ERP-, or multimodal approaches. AI: artificial intelligence; AUC: area under the curve; CNN: convolutional neural network; DTI: diffusion tensor imaging; EEG: electroencephalography; ERP: event-related potential; LSTM: long short-term memory; MRI: magnetic resonance imaging; SZ: schizophrenia.
Declarations
Disclaimer
Declaration of AI and AI-assisted technologies in the writing process: during the preparation of this work, the authors used Grammarly and QuillBot for English language refinement. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the manuscript.
Acknowledgments
The authors are thankful to their respective institutions for providing academic support during the preparation of this review article.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Patel S, Patel K, Patel A. Artificial intelligence: ways and means for central nervous system (CNS) delivery. In: Patel V, Singh RM, Shah JS, Mehta T, editors. Targeted Therapy for the Central Nervous System. Elsevier; 2025. pp. 325–48. [DOI]
Kale M, Wankhede N, Pawar R, Ballal S, Kumawat R, Goswami M, et al. AI-driven innovations in Alzheimer’s disease: integrating early diagnosis, personalized treatment, and prognostic modelling.Ageing Res Rev. 2024;101:102497. [DOI] [PubMed]
Jiang S, Jia Q, Peng Z, Zhou Q, An Z, Chen J, et al. Can artificial intelligence be the future solution to the enormous challenges and suffering caused by schizophrenia?Schizophrenia (Heidelb). 2025;11:32. [DOI] [PubMed] [PMC]
Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.World Psychiatry. 2015;14:119–36. [DOI] [PubMed] [PMC]
Baran FDE, Cetin M. AI-driven early diagnosis of specific mental disorders: a comprehensive study.Cogn Neurodyn. 2025;19:70. [DOI] [PubMed] [PMC]
Brady LS, Lisanby SH, Gordon JA. New directions in psychiatric drug development: promising therapeutics in the pipeline.Expert Opin Drug Discov. 2023;18:835–50. [DOI] [PubMed]
Yingngam B. AI-driven drug discovery. In: Jena B, Saxena S, Paul S, editors. Machine Learning for Neurodegenerative Disorders: Advancements and Applications. CRC Press; 2025. p. 80.
Tettey-Engmann F, Parupelli SK, Bauer SR, Bhattarai N, Desai S. Advances in artificial intelligence-based medical devices for healthcare applications.Biomed Mater Devices. 2026;4:1767–87. [DOI]
Hasanzad M, Nosrati M, Khatami F, Rahmani P, Sarhangi N, Nikfar S, et al. Drug discovery in the context of precision medicine and artificial intelligence.Expert Rev Precis Med Drug Dev. 2024;9:42–53. [DOI]
Paraschiv EA, Băjenaru L, Petrache C, Bica O, Nicolau D. AI-driven neuro-monitoring: advancing schizophrenia detection and management through deep learning and EEG analysis.Future Int. 2024;16:424. [DOI]
Omiyefa S. Artificial intelligence and machine learning in precision mental health diagnostics and predictive treatment models.Int J Res Publ Rev. 2025;6:85–99.
Ajayi R. AI-powered innovations for managing complex mental health conditions and addiction treatments.Int Res J Mod Eng Technol Sci. 2025;7:87. [DOI]
Dhariwal N, Sengupta N, Madiajagan M, Patro KK, Kumari PL, Samee NA, et al. A pilot study on AI-driven approaches for classification of mental health disorders.Front Hum Neurosci. 2024;18:1376338. [DOI] [PubMed] [PMC]
Oyeniyi J, Oluwaseyi P. Emerging trends in AI-powered medical imaging: enhancing diagnostic accuracy and treatment decisions.Int J Enhanced Res Sci Technol Eng. 2024;13:81–94.
Alanazi MMF, Almutairi SFM, Alarjani NO, Alghaylan MYA, Aljawhari MSM, Alkhulaifi AAS. Advancements in AI-driven diagnostic radiology: enhancing accuracy and efficiency.Int J Health Sci. 2024;8:1402–14. [DOI]
Kothinti RR. Deep learning in healthcare: transforming disease diagnosis, personalized treatment, and clinical decision-making through AI-driven innovations.World J Adv Res Rev. 2024;24:2841–56. [DOI]
Çabuk T, Sevim N, Mutlu E, Yağcıoğlu AEA, Koç A, Toulopoulou T. Natural language processing for defining linguistic features in schizophrenia: a sample from Turkish speakers.Schizophr Res. 2024;266:183–9. [DOI] [PubMed]
Dalal TC, Liang L, Silva AM, Mackinley M, Voppel A, Palaniyappan L. Speech-based natural language profile before, during, and after the onset of psychosis: a cluster analysis.Acta Psychiatr Scand. 2025;151:332–47. [DOI] [PubMed] [PMC]
Tejaswini V, Sathya Babu K, Sahoo B. Depression detection from social media text analysis using natural language processing techniques and hybrid deep learning model.ACM Trans Asian Low-Resour Lang Inf Process. 2024;23:1–20. [DOI]
Brahmi Z, Mahyoob M, Al-Sarem M, Algaraady J, Bousselmi K, Alblwi A. Exploring the role of machine learning in diagnosing and treating speech disorders: a systematic literature review.Psychol Res Behav Manag. 2024;17:2205–32. [DOI] [PubMed] [PMC]
Bacon EJ, He D, Achi NAD, Wang L, Li H, Yao-Digba PDZ, et al. Neuroimage analysis using artificial intelligence approaches: a systematic review.Med Biol Eng Comput. 2024;62:2599–627. [DOI] [PubMed]
Lamprou Z. Towards brain-computer interface-based information systems: leveraging machine learning for cognitive interaction [dissertation]. Glasgow: University of Strathclyde; 2025.
Dehgan A. Enhancing electrophysiology imaging through artificial intelligence [dissertation]. Montréal: Université de Montréal; 2025.
Han Y. Assessing pain from neurophysiological signals: machine learning approaches using functional connectivity [dissertation]. Essex: University of Essex; 2024.
Naved BA. Using multivariate statistics and machine learning to reveal gait as a pre-clinical biomarker of injury, disease, and age [dissertation]. Evanston: Northwestern University; 2024.
Hughes JW. From beats to biomarkers: unlocking the power of cardiac diagnostic tools with artificial intelligence [dissertation]. Stanford: Stanford University; 2024.
Østergaard FG, Kas MJH. Seven unique frequency profiles for scoring vigilance states in preclinical electrophysiological data.Front Neurosci. 2025;19:1488709. [DOI] [PubMed] [PMC]
Sanches PHG, de Melo NC, Porcari AM, de Carvalho LM. Integrating molecular perspectives: strategies for comprehensive multi-omics integrative data analysis and machine learning applications in transcriptomics, proteomics, and metabolomics.Biology (Basel). 2024;13:848. [DOI] [PubMed] [PMC]
Yıldız GG. Multi-omics data integration in the prediction of potential biomarkers and therapeutics in human cancers [dissertation]. Turkey: Marmara Universitesi; 2024.
Chu A. Multimodal and multiomic integration in precision oncology [dissertation]. Michigan: University of Michigan; 2025.
Mosquera FEC, Guevara-Montoya MC, Serna-Ramirez V, Liscano Y. Neuroinflammation and schizophrenia: new therapeutic strategies through psychobiotics, nanotechnology, and artificial intelligence (AI).J Pers Med. 2024;14:391. [DOI] [PubMed] [PMC]
Aziz S, Khan MU, Iqtidar K, Fernandez-Rojas R. Diagnosis of schizophrenia using EEG sensor data: a novel approach with automated log energy-based empirical wavelet reconstruction and cepstral features.Sensors (Basel). 2024;24:6508. [DOI] [PubMed] [PMC]
SupriyaPatro P, Goel T, VaraPrasad SA, Tanveer M, Murugan R. Lightweight 3D convolutional neural network for schizophrenia diagnosis using MRI images and ensemble bagging classifier.Cognit Comput. 2024;16:2019–35. [DOI]
Hu M, Qian X, Liu S, Koh AJ, Sim K, Jiang X, et al. Structural and diffusion MRI based schizophrenia classification using 2D pretrained and 3D naive Convolutional Neural Networks.Schizophr Res. 2022;243:330–41. [DOI] [PubMed]
Wang J, Lu X, Fei N, Li X, Hu Y. Application of CNN classifier for somatosensory ERP-based brain-computer interface. In: 2024 IEEE International Conference on Computational Intelligence and Virtual Environments for Measurement Systems and Applications (CIVEMSA); 2024 Jun 14–16; Xi’an, China. IEEE; 2024. pp. 1–6.
Dening TJ, Rao S, Thomas N, Prestidge CA. Oral nanomedicine approaches for the treatment of psychiatric illnesses.J Control Release. 2016;223:137–56. [DOI] [PubMed]
Baboota S, Ali J. Combination antipsychotics therapy for schizophrenia and related psychotic disorders interventions: emergence to nanotechnology and herbal drugs.J Drug Deliv Sci Technol. 2021;61:102272. [DOI]
Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing.Mol Pharm. 2010;7:1388–405. [DOI] [PubMed] [PMC]
Rajendran R, Menon KN, Nair SC. Nanotechnology approaches for enhanced CNS drug delivery in the management of schizophrenia.Adv Pharm Bull. 2022;12:490–508. [DOI] [PubMed] [PMC]
Wani SN, Singh S, Sharma N, Zahoor I, Grewal S, Gupta SJB. Transferosome-based intranasal drug delivery systems for the management of schizophrenia: a futuristic approach.BioNanoScience. 2024;14:3811–29. [DOI]
Kondej M, Stępnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia.Int J Mol Sci. 2018;19:3105. [DOI] [PubMed] [PMC]
Rathi R, Mehetre NM, Goyal S, Singh I, Huanbutta K, Sangnim T. Advanced drug delivery technologies for enhancing bioavailability and efficacy of risperidone.Int J Nanomedicine. 2024;19:12871–87. [DOI] [PubMed] [PMC]
Suri K, Wolfram J, Shen H, Ferrari M. Advances in nanotechnology-based drug delivery platforms and novel drug delivery systems. In: Singh M, Salnikova M, editors. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Elsevier; 2015. pp. 41–58.
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery.J Pharm Investig. 2013;43:353–62. [DOI]
Shirodkar RK, Kumar L, Mutalik S, Lewis S. Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid-based drug delivery systems.Pharm Chem J. 2019;53:440–53. [DOI]
Milović M, Simović S, Lošić D, Dashevskiy A, Ibrić S. Solid self-emulsifying phospholipid suspension (SSEPS) with diatom as a drug carrier.Eur J Pharm Sci. 2014;63:226–32. [DOI] [PubMed]
Piazza JE. Novel antipsychotic drug carriers: the development of nanoparticle and microgel drug carriers for antipsychotic delivery in the treatment of schizophrenia [dissertation]. Hamilton: McMaster University; 2013.
Bakshi HA, Quinn GA, Aljabali AAA, Hakkim FL, Farzand R, Nasef MM, et al. Exploiting the metabolism of the gut microbiome as a vehicle for targeted drug delivery to the colon.Pharmaceuticals (Basel). 2021;14:1211. [DOI] [PubMed] [PMC]
Rehman S, Nabi B, Pottoo FH, Baboota S, Ali J. Nanoparticle-based gene therapy approach: a pioneering rebellion in the management of psychiatric disorders.Curr Gene Ther. 2020;20:164–73. [DOI] [PubMed]
de Filippis R, De Fazio P, Gaetano R, Steardo L, Cedro C, Bruno A, et al. Current and emerging long-acting antipsychotics for the treatment of schizophrenia.Expert Opin Drug Saf. 2021;20:771–90. [DOI] [PubMed]
Liang B, Han B, Shi Y, Li X, Zhao W, Kastelic J, et al. Efficacy of phage cocktail against Klebsiella pneumoniae infection of murine mammary glands.Microb Pathog. 2023;182:106218. [DOI] [PubMed]
Liu B, Christopoulos A, Thal DM, Capuano B, Valant C, Scammells PJ. The prosperity and adversity of M4 muscarinic acetylcholine receptor activators in the treatment of neuropsychiatric disorders.J Med Chem. 2025;68:7932–54. [DOI] [PubMed]
Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Therapeutic effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial.Int J Neuropsychopharmacol. 2024;28:pyae061. [DOI] [PubMed] [PMC]
Sharma S, Tyagi A, Dang S. Nose-to-brain delivery of transferrin-conjugated PLGA nanoparticles for clonidine.Int J Biol Macromol. 2023;252:126471. [DOI] [PubMed]
Nayak U, Halagali P, Panchal KN, Tippavajhala VK, Mudgal J, Radhakrishnan R, et al. Nanoparticles in CNS therapeutics: pioneering drug delivery advancements.Curr Pharm Des. 2025;31:443–60. [DOI] [PubMed]
Rai G, Sharma S, Singh A, Chandekar V, Rastogi A, Gauba P, et al. Nanotechnological advancement for the treatment of neurodegenerative disorders.J Dispersion Sci Technol. 2026;47:1073–91. [DOI]
Padmini S, Amaran S, Sreekumar K, Kalaivani J, Iniyan S. Artificial intelligence-enhanced nanomedicine design and deep reinforcement learning in pharmacokinetics. In: Shaik A, editor. AI-Powered Advances in Pharmacology. IGI Global Scientific Publishing; 2025. pp. 135–68.
Amoako K, Mokhammad A, Malik A, Yesudasan S, Wheba A, Olagunju O, et al. Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation.Front Med Technol. 2025;7:1591119. [DOI] [PubMed] [PMC]
Wu C, Luedtke AR, Sadikova E, Tsai H, Liao S, Liu C, et al. Development and validation of a machine learning individualized treatment rule in first-episode schizophrenia.JAMA Netw Open. 2020;3:e1921660. [DOI] [PubMed] [PMC]
Maciejewski M, Lounkine E, Whitebread S, Farmer P, DuMouchel W, Shoichet BK, et al. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets.Elife. 2017;6:e25818. [DOI] [PubMed] [PMC]
Dong J, Gao H, Ouyang D. PharmSD: A novel AI-based computational platform for solid dispersion formulation design.Int J Pharm. 2021;604:120705. [DOI] [PubMed]
Jiang J. Overcoming challenges of solid dosage formulation development by using emerging technologies [dissertation]. Austin: The University of Texas at Austin; 2023.
Shiwlani A, Kumar S, Kumar S, Qureshi HA, Naguib JS. AI-assisted genotype analysis of hepatitis viruses: a systematic review on precision therapy and sequencing innovations.Int J Comput Eng Technol. 2024;6:1–27.
Heyward JS, Segal JB, Mehta HB, Murray JC. Validation of immune-related adverse event (irAE) case definitions in a real-world lung cancer population.Pharmacoepidemiol Drug Saf. 2025;34:e70100. [DOI] [PubMed] [PMC]
Björneld O, Löwe W. Real-World Validation of a Framework for Automated Knowledge-driven Feature Engineering (Akdfe) Inspired by Medical Domain Experts.SSRN 4688970 [Preprint]. [cited 2026 May 11]. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4688970
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development.Drug Discov Today. 2021;26:80–93. [DOI] [PubMed] [PMC]
Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, et al. Tumor microenvironment signaling and therapeutics in cancer progression.Cancer Commun (Lond). 2023;43:525–61. [DOI] [PubMed] [PMC]
Li Z, Ruan M, Chen J, Fang Y. Major depressive disorder: advances in neuroscience research and translational applications.Neurosci Bull. 2021;37:863–80. [DOI] [PubMed] [PMC]
Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K, et al. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.Discov Oncol. 2024;15:342. [DOI] [PubMed] [PMC]
Agache I, Eguiluz-Gracia I, Cojanu C, Laculiceanu A, Giacco SD, Zemelka-Wiacek M, et al. Advances and highlights in asthma in 2021.Allergy. 2021;76:3390–407. [DOI] [PubMed]
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.Pharmacopsychiatry. 2018;51:e1. [DOI] [PubMed]
Leivaditis V, Maniatopoulos AA, Lausberg H, Mulita F, Papatriantafyllou A, Liolis E, et al. Artificial intelligence in thoracic surgery: a review bridging innovation and clinical practice for the next generation of surgical care.J Clin Med. 2025;14:2729. [DOI] [PubMed] [PMC]
Tistelgrén S. Artificial intelligence in software development: exploring utilisation, tools, and value creation [dissertation]. Vaasa: Yrkeshögskolan Novia; 2024.
Albalawi A. Cloud security and data protection in hybrid environments. In: Aldweesh AY, editor. Complexities and Challenges for Securing Digital Assets and Infrastructure. IGI Global Scientific Publishing; 2025. pp. 175–98.
Misra S, Katz B, Roberts P, Carney M, Valdivia I. Toward a person-environment fit framework for artificial intelligence implementation in the public sector.Gov Inf Q. 2024;41:101962. [DOI]
Fusar-Poli P, Manchia M, Koutsouleris N, Leslie D, Woopen C, Calkins ME, et al.; PSMD EBRA cluster (annex 1). Ethical considerations for precision psychiatry: A roadmap for research and clinical practice.Eur Neuropsychopharmacol. 2022;63:17–34. [DOI] [PubMed]
Dey H, Arya N, Mathur H, Chatterjee N, Jadon R. Exploring the role of artificial intelligence and machine learning in pharmaceutical formulation design.Int J Newgen Res Pharm Healthcare. 2024;1:30–41.
Shanmuga Sundari M, Penthala HR, Mogullapalli A, Ammangatambu MM. AI-based personalized drug treatment. In: Khanna A, Barachi ME, Jain S, Kumar M, Nayyar A, editors. Artificial Intelligence and Machine Learning in Drug Design and Development. Scrivener Publishing LLC; 2024. pp. 369–406.
Saini JPS, Thakur A, Yadav D. AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations.RSC Pharm. 2025;2:437–54. [DOI]
Kumar A. AI-driven precision oncology: predictive biomarker discovery and personalized treatment optimization using genomic data.Int J Adv Res Publ Rev. 2024;1:21–38. [DOI]
Elbadawi M, Li H, Sun S, Alkahtani ME, Basit AW, Gaisford S. Artificial intelligence generates novel 3D printing formulations.Appl Mater Today. 2024;36:102061. [DOI]
Min J. Innovations in wireless bioelectronics for precision medicine, from sustainable sweat sensing to ingestible gut monitoring [dissertation]. California: California Institute of Technology; 2023.
Das HS, Maity S. Integrating Internet of Things (IoT) with edible electronics. In: Mehta S, Al-Turjman F, editors. Edible Electronics for Smart Technology Solutions. IGI Global Scientific Publishing; 2025. pp. 237–64.
Koruprolu A, Hack T, Ghadami O, Jain A, Hall DA. From wearables to implantables: harnessing sensor technologies for continuous health monitoring.IEEE Trans Biomed Circuits Syst. 2025;19:852–75. [DOI] [PubMed]
Thwaites PA, Yao CK, Halmos EP, Muir JG, Burgell RE, Berean KJ, et al. Review article: current status and future directions of ingestible electronic devices in gastroenterology.Aliment Pharmacol Ther. 2024;59:459–74. [DOI] [PubMed] [PMC]
Lu T, Ji S, Jin W, Yang Q, Luo Q, Ren TL. Biocompatible and Long-Term Monitoring Strategies of Wearable, Ingestible and Implantable Biosensors: Reform the Next Generation Healthcare.Sensors (Basel). 2023;23:2991. [DOI] [PubMed] [PMC]
Teng X. An embodied interactive product based on gastrointestinal sensory response to women’s healthy eating problems [dissertation]. Espoo: Aalto University; 2025.
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence.Nat Med. 2019;25:44–56. [DOI] [PubMed]
Ferdousi R. Digital twin disease diagnosis using machine learning [dissertation]. Ottawa: University of Ottawa; 2021.
Ebnali M, Ahmadi N, Nabiyouni E, Karimi H. AI-powered human digital twins in virtual therapeutic sessions. In: Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care. SAGE; 2023. pp. 1–4.
Paramasivan A. AI and digital twin technology: personalized simulations for improving patient-specific treatment plans.Int J Sci Adv Technol. 2024;15:1–15.
Shafik W. The next generation of health monitoring: digital twins and medical wearables. In: Balasubramaniam S, Seifedine K, editors. AI-Powered Digital Twins for Predictive Healthcare: Creating Virtual Replicas of Humans. IGI Global Scientific Publishing; 2025. pp. 69–106.
Qian K, Suarez GO, Nambara T, Kanekiyo T, Zhang YJ. High-throughput digital twin framework for predicting neurite deterioration using MetaFormer attention.arXiv 2501.08334 [Preprint]. [cited 2026 May 11]. Available from: https://doi.org/10.48550/arXiv.2501.08334
Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.J Control Release. 2016;240:504–526. [DOI] [PubMed] [PMC]
Char DS, Shah NH, Magnus D. Implementing Machine Learning in Health Care - Addressing Ethical Challenges.N Engl J Med. 2018;378:981–3. [DOI] [PubMed] [PMC]
Wei Q, Pan S, Liu X, Hong M, Nong C, Zhang W. The integration of AI in nursing: addressing current applications, challenges, and future directions.Front Med (Lausanne). 2025;12:1545420. [DOI] [PubMed] [PMC]
Galetsi P, Katsaliaki K, Kumar S. Values, challenges and future directions of big data analytics in healthcare: a systematic review.Soc Sci Med. 2019;241:112533. [DOI] [PubMed]
Hang L, Chen C, Zhang L, Yang J. Blockchain for applications of clinical trials: taxonomy, challenges, and future directions.IET Commun. 2022;16:2371–93. [DOI]
Ahmad K, Maabreh M, Ghaly M, Khan K, Qadir J, Al-Fuqaha A. Developing future human-centered smart cities: critical analysis of smart city security, data management, and ethical challenges.Comput Sci Rev. 2022;43:100452. [DOI]
Makhlouf K. Advancing ethical and responsible AI: exploring fairness, privacy, and explainability through causal perspectives [dissertation]. Paris: École Polytechnique; 2024.
Akhtar MAK, Kumar M, Nayyar A. Privacy and security considerations in explainable AI. In: Akhtar MAK, Kumar M, editors. Towards Ethical and Socially Responsible Explainable AI. Cham: Springer Nature Switzerland; 2024. pp. 193–226.
Akhtar MAK, Kumar M, editors. Towards Ethical and Socially Responsible Explainable AI. Cham: Springer Nature Switzerland; 2024.
Goethals S. Explaining prediction models to address ethical issues in business and society [dissertation]. Antwerp: University of Antwerp; 2024.
Bura C, Kamatala S, Myakala PK. Ethical challenges in data science: navigating the complex landscape of responsibility and fairness.Int J Curr Sci Res Rev. 2025;8:221–30.
Li Z. Ethical frontiers in artificial intelligence: navigating the complexities of bias, privacy, and accountability.Int J Eng Manage Res. 2024;14:109–16. [DOI]
Li T, Sahu AK, Talwalkar A, Smith V. Federated learning: challenges, methods, and future directions.IEEE Signal Process Mag. 2020;37:50–60. [DOI]
Isik L, Nilsson C, Magnusson J, Koutsikouri D. Benefits realization in digital transformation: the translation from policy to practice in health care.Transform Gov People Process Policy. 2024;18:303–17. [DOI]
Lucena MI, Villanueva-Paz M, Alvarez-Alvarez I, Aithal GP, Björnsson ES, Cakan-Akdogan G, et al. Roadmap to DILI research in Europe: a proposal from COST Action ProEuroDILINet.Pharmacol Res. 2024;200:107046. [DOI] [PubMed] [PMC]
Benjamens S, Dhunnoo P, Meskó B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database.NPJ Digit Med. 2020;3:118. [DOI] [PubMed] [PMC]
Rieke N, Hancox J, Li W, Milletarì F, Roth HR, Albarqouni S, et al. The future of digital health with federated learning.NPJ Digit Med. 2020;3:119. [DOI] [PubMed] [PMC]
Meskó B, Görög M. A short guide for medical professionals in the era of artificial intelligence.NPJ Digit Med. 2020;3:126. [DOI] [PubMed] [PMC]